Gland Pharma to Make US Arm Direct Wholly-Owned Subsidiary

Gland Pharma will acquire a 100% stake in Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd. for a cash consideration of $501,208, simplifying its corporate structure. Key Highlights • Gland Pharma will acquire 100% equity of Gland Pharma USA Inc. • Consideration: $501,208, payable in cash. • Following the transaction, Gland Pharma USA will become a direct wholly-owned subsidiary of Gland Pharma. • The US entity is engaged in the marketing and distribution of pharmaceutical products in the United States. • Turnover stood at $87,342 in FY25, compared with $483,808 in FY24, while FY26 turnover was nil. • The acquisition is expected to be completed by October 31, 2026. Why It Matters This is primarily a corporate restructuring rather than an external acquisition, as Gland Pharma USA is being acquired from another group entity. The transaction simplifies the ownership structure by bringing the US marketing and distribution entity directly under Gland Pharma. Given the relatively small consideration and nil FY26 turnover of the US entity, the immediate financial impact appears limited. The key significance is the simplification of Gland Pharma’s US corporate structure.